Research programme: plasma-derived biopharmaceuticals - Liminal BioSciences/ProThera Biologics
Alternative Names: IaIp - Liminal BioSciences; Inter alpha-one inhibitor proteins; Inter-alpha inhibitor proteins - Liminal BioSciencesLatest Information Update: 28 Mar 2022
At a glance
- Originator ProMetic Life Sciences; ProThera Biologics
- Developer Liminal BioSciences; ProThera Biologics
- Class Anti-inflammatories; Proteins
- Mechanism of Action Serine protease inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Inflammation; Necrotising enterocolitis
Most Recent Events
- 28 Mar 2022 No recent reports of development identified for preclinical development in Necrotising enterocolitis in USA
- 28 Dec 2019 No recent reports of development identified for research development in Inflammation in Canada
- 03 Oct 2019 Prometic Life Sciences is now called Liminal BioSciences